Category: Stent Wars
Conor MedSystems, the stent maker Johnson & Johnson acquired in 2007, must face a $100 million Biotronik breach-of-contract lawsuit, a New York state appeals court rules.
Johnson & Johnson (NYSE:JNJ) subsidiary Conor MedSystems can't slip a $100 million breach of contract lawsuit filed by former European distribution partner Biotronik, a New York state appeals court ruled last week.
Abbott says the Dutch Supreme Court upheld its win over Medinol, ending the patent infringement lawsuit brought by the Israeli coronary stent maker.
Seven-year results from Boston Scientific's MADIT-CRT trial show long-term benefits for some patients with mild heart failure.
Some patients with mild heart failure show significant, long-term benefits from cardiac-resynchronization therapy, according to the 7-year results from Boston Scientific's (NYSE:BSX) MADIT-CRT clinical trial presented at the American College of Cardiology's annual meeting over the weekend.
Medtech titan Medtronic touts a relatively minor clinical trial win for the physical integrity of its Resolute drug-eluting stent in what is otherwise a tie with Boston Scientific's Promus Element device.
The U.S. Supreme Court denies stent pioneer Dr. Bruce Saffran's appeal of a $600 million patent infringement decision to Johnson & Johnson's Cordis stent-making arm.
Johnson & Johnson's (NYSE:JNJ) Cordis stent-making arm won the final round in a patent infringement battle with stent pioneer Dr. Bruce Saffran when the U.S. Supreme Court yesterday declined to hear Saffran's appeal.
The FDA grants pre-market approval to Boston Scientific's next-generation Promus Premier coronary stent.
Boston Scientific (NYSE:BSX) said the FDA granted pre-market approval for its next-generation coronary stent, the Promus Premier.
Natick, Mass.-based Boston Scientific said it plans an immediate release for the Promus Premier, a drug-eluting stent made of a platinum-chromium alloy coated with everolimus.
The U.S. Court of Appeals for the Federal Circuit declines to revisit its decision to uphold a lower court's decision to invalidate patents for drug-eluting coronary stent technology.
A federal appeals court last week declined to revisit its decision to uphold the invalidation of patents covering drug-eluting stent technology.